Orally active, selective inhibitor of VEGF receptor kinase activity; also inhibits EGFR and RET tyrosine kinases
Vandetanib is an orally active and potent inhibitor of vascular endothelial growth factor receptor receptor 2 (VEGFR2) kinase activity that is used to treat medullary thyroid cancer. Vandetanib also inhibits epidermal growth factor receptor (EGFR), and RET tyrosine kinases.
International journal of molecular sciences, 21(1) (2019-12-22)
Thyroid cancer is the most common endocrine malignancy. Most thyroid cancer types respond well to conventional treatment consisting of surgery and radioactive iodine (RAI) therapy. Unfortunately, some thyroid cancer types are resistant to surgical and RAI therapy. Multikinase inhibitors (MKIs)
RET/papillary thyroid carcinoma (PTC) oncogenes, generated by recombination of the tyrosine kinase-encoding domain of RET with different heterologous genes, are prevalent in papillary carcinomas of the thyroid. Point mutations of RET cause multiple endocrine neoplasia type 2 (MEN2) familial cancer
Journal of medicinal chemistry, 45(6), 1300-1312 (2002-03-08)
We have previously shown that 4-anilinoquinazolines can be potent inhibitors of vascular endothelial growth factor (VEGF) receptor (Flt-1 and KDR) tyrosine kinase activity. A novel subseries of 4-anilinoquinazolines that possess basic side chains at the C-7 position of the quinazoline
Questions
Évaluations
★★★★★ Aucune valeur de notation
Filtres actifs
Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..
